Adding tucatinib to first-line maintenance therapy delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy,…

Continue Reading

News Source: medicalxpress.com